Despite continuous improvement in survival, patients with multiple myeloma (MM) still relapse, and survival after failure of proteasome inhibitor (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies remains poor. Here, CD38 is linked to AL amyloidosis.